Urgent Care News

A few months ago, we shared the findings of a study published in the Journal of the American Medical Association indicating that a 5-day course of remdesivir improved outcomes for hospitalized patients with “moderate-to-severe” COVID-19. Further study by another group of researchers now shows that a 3-day course reduced risk for hospitalization or death in patients with COVID-19 and certain comorbidities but who had not yet been hospitalized with the virus. The latest study, published …

The sharp rise in COVID-19 cases attributed to the Omicron variant so close after the winter holidays is a nonscientific (but probably accurate) indicator that people spent a lot of time in tight quarters, unmasked, with others whose immunization or exposure status was unknown to them. The more ominous prospect, given that many individuals got rapid tests (or insisted that visitors do so) before gathering, is that rapid antigen tests may not be much help …

Due to supply chain concerns and the ongoing rapid rise in COVID-19 cases in the United States, the U.S. Department of Health and Human Services says it is moving to a weekly allocation cycle for related therapeutics for 3 weeks, starting January 3. HHS says it has stopped allocating bam/ete or Regen-COV to jurisdictions with 80% or more prevalence of the Omicron variant, given that data from the Centers for Disease Control and Prevention indicate …

This is the second flu season in a row that the healthcare community has held its breath waiting to see if the United States would be hit with dual widespread outbreaks of COVID-19 and influenza (aka, a twindemic). And so far, in spite of another COVID surge fueled by the Omicron variant, so good on that front. However, public health officials here and in other countries are reporting an increase in flurona—or, simultaneous diagnoses of …

New data from the UK Health Security Agency indicate that booster shot protection against symptomatic COVID-19 caused by the Omicron variant fades within 10 weeks or so. There’s no indication as to whether that means boosters are any more or less successful at preventing severe disease in those who do become infected with the Omicron variant of the virus. The research shows that providing two doses of the AstraZeneca vaccine (available in the UK but …

The Food and Drug Administration officially blessed the practice of providing COVID-19 booster shots to 12- to 15-year-old children, as well as for immunocompromised children between 5 and 11 years of age. In the same announcement, the FDA shortened the recommended interval between initial vaccination and boosters for some patients. Based on “new evidence,” the agency suggests that patients who received two doses of the Pfizer vaccine get a booster shot 5 months after completing …